Combined Inhibition of XPO1 and DNA Methylation Exerts Synergistic Effects in DLBCL
Molecular Carcinogenesis · 2025-10 · 64 (10) · 1609-1619
DOI: 10.1002/mc.70014 ↗At a glance
Journal article in Molecular Carcinogenesis, published online on 2025-07-13. Written by Qi Li and 10 co-authors. Institution: Department of Hematology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. Major MEDLINE topics: Lymphoma, Large B-Cell, Diffuse, DNA Methylation, Hydrazines, Receptors, Cytoplasmic and Nuclear. Cited 1 times so far (Crossref); 43 references. Funded by: The research leading to these results has received funding from National Natural Science Foundation of China (82270211; 82270197; 82470199); Suzhou City Basic….
Abstract (original language)
Diffuse large B‐cell lymphoma (DLBCL) is an aggressive type of non‐Hodgkin lymphoma characterized by high rates of relapse and limited responsiveness to standard chemotherapy. Selinxor, a selective inhibitor of XPO1, exhibited antitumor activity in various cancers. However, clinical trial results revealed that selinexor monotherapy exhibited unsatisfactory efficacy in DLBCL. Our study indicated that XPO1 expression was increased in DLBCL and was correlated with poor outcomes of DLBCL patients. Comprehensive proteomic and transcriptomics analysis showed that selinexor has significant impacts on various biological processes in DLBCL. Furthermore, we explored combination strategies involving selinexor to enhance DLBCL treatment. We examined the combined effects of selinexor with decitabine (DAC) and lenalidomide (LEN), and found that selinexor exhibited a synergistic effect with DAC against DLBCL. Further analysis revealed that DAC exerted a synergistic antitumor effect with selinexor by reversing the DNMT1 expression and DNA methylation alterations induced by selinexor. Overall, these findings provided valuable insights into the global impact of selinexor on DLBCL. The combination therapy of selinexor and DAC emerges as a highly promising strategy for effectively treating DLBCL, holding great potential for clinical application.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Hematology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
- Suzhou Sano Precision Medicine Ltd., Suzhou, Jiangsu, China.
- Department of Cell Biology, School of Basic Medical Sciences, Soochow University, Suzhou, Jiangsu, China.
ORCID profiles: Bingzong Li
Funding
- The research leading to these results has received funding from National Natural Science Foundation of China (82270211; 82270197; 82470199); Suzhou City Basic…
Cite
APA
Li, Q., Xue, X., Chen, S., Zhang, X., Zhang, Y., Hu, R., Zhang, X., Qin, L., Chen, M., Zhuang, W., & Li, B. (2025). Combined Inhibition of XPO1 and DNA Methylation Exerts Synergistic Effects in DLBCL. Molecular Carcinogenesis, 64(10), 1609-1619. https://doi.org/10.1002/mc.70014
Vancouver
Li Q, Xue X, Chen S, Zhang X, Zhang Y, Hu R, et al. Combined Inhibition of XPO1 and DNA Methylation Exerts Synergistic Effects in DLBCL. Molecular Carcinogenesis. 2025;64(10):1609-1619. doi:10.1002/mc.70014
BibTeX
@article{Li2025,
author = {Li, Qi and Xue, Xiaofeng and Chen, Si and Zhang, Xinyun and Zhang, Yuchen and Hu, Ruijing and Zhang, Xinyuan and Qin, Linlin and Chen, Menglu and Zhuang, Wenzhuo and Li, Bingzong},
title = {Combined Inhibition of XPO1 and DNA Methylation Exerts Synergistic Effects in DLBCL},
journal = {Molecular Carcinogenesis},
year = {2025},
volume = {64},
number = {10},
pages = {1609--1619},
doi = {10.1002/mc.70014}
}
EUVIMED